Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
November 14, 2011

Geron announces shift from stem cell research to oncology

Geron Corporation has announced that it will discontinue further development of its stem cell programmes to focus on its first-in-class oncology ones.

By Daniel Garrun

Geron Corporation has announced that it will discontinue further development of its stem cell programmes to focus on its first-in-class oncology ones.

Geron CEO John Scarlett, MD, said that in the current environment of capital scarcity and uncertain economic conditions the company intends to focus resources on advancing Phase II clinical trials of imetelstat and GRN1005

These two novel and promising oncology drug candidates target major unmet medical needs and have important clinical development milestones occurring over the next 20 months," said Scarlett.

Imetelstat, is currently being evaluated in four Phase II clinical oncology studies for non-small cell lung cancer, breast cancer, essential thrombocythemia and multiple myeloma.

According to the company the decision to narrow Geron’s technology and therapeutic focus was made after a strategic review of the costs, value inflection timelines and clinical, manufacturing and regulatory complexities.

With this decision, Geron will also eliminate 66 full-time positions, representing 38% of its workforce.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining

The company also expects a one-time cash expenditure of approximately $5m in the fourth quarter of 2011 and approximately $3m in the first half of 2012.

Geron is seeking partners with the technical and financial resources to enable further development of its stem cell programmes.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU